Fig. 2From: Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in ChinaThe development process of eight national anti-PD1 and PD-L1 inhibitors. The agents on the left were approved by the Chinese Food and Drug Administration for clinical trials, and the agents on the right have applied for clinical trial approval. Blue rectangles indicate PD-1 inhibitors, and orange rectangles indicate PD-L1 inhibitorsBack to article page